摘要
目的检测抑凋亡蛋白Survivin及多药耐药基因mdr1的表达蛋白P-糖蛋白(P-gp)在卵巢上皮性癌中的表达,分析其在卵巢癌化学治疗耐药中的作用及与临床病理学特征间的关系。方法应用免疫组织化学技术SP法检测8例正常卵巢组织、16例良性上皮性卵巢肿瘤、46例上皮性卵巢癌(浆液性癌28例、粘液性癌12例、内膜样癌6例)组织中的Survivin、P-gp蛋白的表达情况。结果Survivin、P-gp蛋白在卵巢癌组织中阳性表达率分别为60.9%和34.8%,显著高于良性上皮性卵巢肿瘤组织31.3%、0%和正常卵巢组织(阴性)(P<0.05)。Survivin蛋白在Ⅲ-Ⅳ期恶性上皮性卵巢肿瘤组中的阳性表达高于Ⅰ-Ⅱ期肿瘤组(P<0.05);在低分化恶性上皮性卵巢肿瘤组织中的阳性表达高于中、高分化肿瘤组,有显著性差异(P<0.05),但与肿瘤组织类型无关。Survivin与P-gp在恶性上皮性卵巢肿瘤组中存在共同表达,卡方检验P<0.05,呈正性相关。结论卵巢癌存在原发性耐药,而由Survivin高表达引起的凋亡抑制在卵巢癌多药耐药的发生中起一定作用。
Objective To detect the expression of inhibitor of apoptosis protein survivin and mdrl gene protein P-gp in ovarian epithelial carcinoma, and analyze their functions of drug resistance in chemotherapy and the relationship with pathological characteristics. Methods We detected the expression of survivin and mdr1 proteins in 8 cases of normal ovarian tissues, 16 cases of benign epithelial ovarian tumor tissues and 46 cases of epithelial ovarian cancerous tissues （28 cases of serous cystadenocarcinoma, 12 cases of mucinous cystadenocarcinoma, and 6 cases of endometrioid carcinoma） with immunohistochemistry. Results The positive rate of survivin and mdrl proteins in ovarian cancerous tissues was 60.9% and 34.8%, respectively, which was significantly higher than that in benign epithelial ovarian tumor tissues （31.3% and 0%） and normal ovarian tissues （negative） （P%0.05）. In epithelial ovarian carcinoma group, the level of survivin expression in stage Ⅲ - Ⅳ was significantly higher than that in stage Ⅰ-Ⅱ , and the positive rate in low differential epithelial ovarian carcinoma tissues was higher than in medium and high differential epithelial ovarian carcinoma tissues （P 〈0.05）. There was no significant difference among different pathological types. There was co-expression of survivin and mdr1 in ovarian epithelial carcinoma, and positive correlation was seen for survivin and mdr1 in chi-square test. Conclusion Primary drug resistance exists in ovarian carcinoma. The abnormal survivin gene expression in ovarian cancerous tissues might induce apoptosis suppression, which might play a role in primary drug resistance and multiple drug resistance in ovarian carcinoma chemotherapy.
出处
《西安交通大学学报（医学版）》
CAS
CSCD
北大核心
2007年第5期578-581,共4页
Journal of Xi’an Jiaotong University（Medical Sciences）
基金
陕西省科技攻关基金资助项目(No.2004K18-G9a)
